Endocrine Abstracts

Introduction: Serotonin producing neuroendocrine tumors are usually well differentiated, small lesions localised in the small intestine. Visualisation of the primary tumor might be difficult due to its small size.Case report: A 52 years old man presented with diarrhoea and flushes. Ultrasound examination and computed tomography of the abdomen revealed numerous lesions in the liver. Gastroscopy, colonoscopy and magnetic resonance imaging did not reveal th...

Introduction: Peptide receptor radionuclide therapy is indicated in case of patients with disseminated neuroendocrine tumors and is usually considered as palliative treatment.Case reports: 55 years old man diagnosed with tumor of the pancreatic head. On laparotomy performed in June 2012 tumor was stated unresectable. Histopathological examination revealed the mixed adeno-neuroendocrine cancer (MANEC). Patient was qualified to chemotherapy with gemcitabin...

Introduction: The aim of this study was to assess the survival rate of patients with disseminated or inoperable neuroendocrine tumors (NETs) after PRRT with the use of 90Y-DOTATATE combined with long acting somatostatin analogue.Materials and methods: 72 patients were treated with PRRT in our Department. The 90Y-DOTATATE therapeutic activity was calculated per total body surface area up to a total of 7.4 GBq/m2 administra...

Introduction: The aim of this study was to assess the efficacy of peptide receptor radionuclide therapy (PRRT) with the use of 90Y-DOTATATE and the survival rate of patients with disseminated or non-operable neuroendocrine tumors (NETs).Methods: In the time period from June 2006 to October 2012, 70 patients were treated with PRRT in our department. The 90Y-DOTATATE therapeutic activity was calculated per total body surface area up t...

Despite a wide spectrum of imaging diagnostics, GEP-NETs often stay undetectable until the time of dissemination. Removing of a primary tumour together with disseminated lymph nodes even with the presence of liver metastases is the most appropriate treatment to delay progression of the disease. SRS followed by RGS gives a possibility to detect occult GEP-NET intra-opratively. 99mTc-HYNIC/EDDA-octreotate, a somatostatin analogue with high affinity to sst2 was applied...

Therapy with labeled somatostatin analogues is the modern approach to patients with disseminated or unresectable NETs expressing somatostatin receptors (SSTR). Octreotate is the somatostatin analogue with high affinity to SSTR type 2, most commonly present in NETs. The aim of the study was to assess the efficacy and toxicity of peptide receptor radionuclide therapy (PRRT) with the use of 90Y labelled Tyr3-octreotate, (90Y-DOTATATE) in NETs....

In the 1980 s the discovery of expression of somatostatin receptors on NET cells made the use of somatostatin analogues in diagnosis and therapy possible.The aim: Of the study was to assess response of targeted radio-nuclide therapy with radio-labelled somatostatin analogue 90Y-[DOTA0,D-Phe1,Tyr3]-octreotate (DOTATATE) in treatment of disseminated NETs.Material and methods: 12 patients (a...

Pancreatic NETs often cause difficulties in imaging diagnostics and optimal diagnostic algorithm is searched for. According to the latest reports MDCT sensitivity amounts 60-90%, MR: 80-90%, SRS: 62-100%, EUS: 70-90%.Aim: Assessment of the usefulness of 99 mTc-EDDA/HYNIC-octreotae scintigraphy in detection of primary and metastatic tumours of pancreatic NET in comparison to CT, EUS and IOUS and evaluation of the impact of scintigraphic results...

Surgery is the only effective therapy for insulinoma patients, therefore there is a necessity to develop diagnostic strategies in cases of unknown tumour location, possibly through the use of new biomarkers. 99mTc labelled glucagon-like peptide 1 analogue (99mTc-GLP1) scintigraphy has been developed in our centre as an imaging technique of insulinoma. Labelled GLP1 analogue might also be applied in diagnosis of various forms of nesidioblastosis allowing t...

Introduction: The aim of this study was to assess the diagnostic efficiency of [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 scintigraphy in the detection of hardly detectable or not diagnosed by other available method insulinomas.Materials and methods: 37 patients (24 women and 13 men, mean age 46.5±17.8 years, min. 16.0 years, max. 77.0 years) were enrolled in this study. There were 32 patients with clinical and bioch...